---
title: "B P Capital Ltd (536965) — Share Price, Financials & Analysis"
symbol: "536965"
company: "B P Capital Ltd"
canonical: "https://tapetide.com/stocks/536965"
isin: "INE947C01010"
bse_code: "536965"
sector: "Financial Services"
industry: "Finance"
market_cap_cr: 5.9
generated_at: "2026-09-13T18:58:43.384Z"
---

# B P Capital Ltd (536965)

Canonical page: https://tapetide.com/stocks/536965

## Company

- **BSE Code:** 536965
- **ISIN:** INE947C01010
- **Sector:** Financial Services
- **Industry:** Finance
- **Macro Sector:** Financial Services
- **Stock Type:** EQUITY
- **Listed Since:** 2013-12-27
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** bpcapital.in

## About

Incorporated in 1994, B P Capital Ltd was registered as a Non-Banking Financial Company[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-07T04:34:01.223406Z.

- **Market Cap:** ₹5.9 Cr
- **Classification:** Microcap
- **P/E (reported):** -32.8
- **EPS (TTM):** ₹-0.3
- **Book Value:** ₹7.21
- **Price to Book:** 1.37
- **Dividend Yield:** 0%
- **ROE:** -3.58%
- **ROCE:** -3.57%
- **Debt to Equity:** 0.22
- **Revenue (yearly):** ₹0 Cr
- **Net Income:** ₹-0.17 Cr
- **EBITDA:** ₹-0.17 Cr
- **52-Week High:** ₹11.42
- **52-Week Low:** ₹7.65

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- Promoter holding is low: 7.06%
- Company has a low return on equity of -3.42% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -9.09% | 14.29% | -0.12% |
| ebitda margin growth | 0% | — | — | — |
| net income growth | 0% | -15% | -8% | -1% |
| revenue growth | 0% | — | — | — |
| roce | — | 17.43% | 22.26% | -4.25% |
| roe | — | 17.76% | -3.18% | -52.39% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 |
| Financing Profit | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 | -0.05 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 | -0.05 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 | -0.05 |
| EPS in Rs | -0.05 | -0.05 | -0.07 | -0.07 | -0.07 | -0.07 | -0.07 | -0.07 | -0.07 | -0.07 | -0.08 | -0.08 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Revenue | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.2 | 0.2 | 0.16 | 0.17 | 0.21 | 0.14 | 0.14 | 0.16 | 0.17 | 0.18 |
| Financing Profit | -0.2 | -0.2 | -0.16 | -0.16 | -0.21 | -0.14 | -0.14 | -0.16 | -0.17 | -0.18 |
| Financing Margin % | — | — | — | -1600 | — | — | — | — | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.2 | -0.2 | -0.16 | -0.16 | -0.21 | -0.14 | -0.14 | -0.16 | -0.17 | -0.18 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net Profit | -0.2 | -0.2 | -0.16 | -0.16 | -0.21 | -0.14 | -0.14 | -0.16 | -0.17 | -0.18 |
| EPS in Rs | -0.66 | -0.66 | -0.53 | -0.53 | -0.35 | -0.23 | -0.23 | -0.27 | -0.28 | -0.3 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 6.01 | 6.01 | 6.01 | 6.01 | 6.01 |
| Reserves | -0.15 | -0.35 | -0.54 | -0.7 | -0.86 | -1.07 | -1.21 | -1.35 | -1.51 | -1.68 |
| Borrowing | 0 | 0 | 0 | 0 | 0 | 0 | 0.82 | 0.93 | 1.05 | 1.19 |
| Other Liabilities | 2.81 | 2.86 | 2.98 | 3.13 | 3.29 | 3.54 | 2.86 | 2.91 | 2.95 | 2.99 |
| Total Liabilities | 5.67 | 5.52 | 5.45 | 5.44 | 5.44 | 8.48 | 8.48 | 8.5 | 8.5 | 8.51 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 |
| Other Assets | 3 | 2.85 | 2.78 | 2.77 | 2.77 | 5.81 | 5.81 | 5.83 | 5.83 | 5.84 |
| Total Assets | 5.67 | 5.52 | 5.45 | 5.44 | 5.44 | 8.48 | 8.48 | 8.5 | 8.5 | 8.51 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -0.22 | 0 | -0.01 | 0 | 0 | -3 | -0.14 | -0.11 | -0.12 | -0.15 |
| Cash from Investing Activity | 0.18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing Activity | 0 | 0 | 0 | 0 | 0 | 3 | 0.14 | 0.11 | 0.12 | 0.14 |
| Net Cash Flow | -0.04 | 0 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -0.22 | 0 | -0.01 | 0 | 0 | -3 | -0.14 | -0.11 | -0.12 | -0.15 |
| CFO/OP | — | 0 | 5 | 0 | 0 | 1429 | 100 | 79 | 75 | 88 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ROE % | 0 | -7.25 | -7.8 | -6.69 | -7.17 | -5.92 | -2.87 | -2.96 | -3.49 | -3.85 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 7.06% | 7.06% | 7.06% | 7.06% | 7.06% | 7.06% | 7.06% | 7.06% | 7.06% | 7.06% | 7.06% | 7.06% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 39.81% | 39.81% | 39.44% | 39.44% | 39.71% | 39.67% | 62.66% | 62.52% | 62.57% | 62.55% | 62.56% | 50.86% |
| Others | 53.13% | 53.13% | 53.5% | 53.5% | 53.23% | 53.27% | 30.28% | 30.42% | 30.37% | 30.4% | 30.38% | 42.08% |
| No. of Shareholders | 1735 | 1734 | 1738 | 1745 | 1750 | 1770 | 1756 | 1743 | 1734 | 1744 | 1748 | 1736 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 11 / 7 / 1

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 10.28 | Buy |
| EMA (10) | 10.01 | Buy |
| SMA (20) | 9.69 | Buy |
| EMA (20) | 9.84 | Buy |
| SMA (50) | 9.08 | Buy |
| EMA (50) | 9.22 | Buy |
| SMA (100) | 7.98 | Buy |
| EMA (100) | 8.39 | Buy |
| SMA (200) | 7.11 | Buy |
| EMA (200) | 7.64 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 57.94 | Neutral |
| MACD (12,26,9) | 0.27 | Sell |
| Stochastic (14,3,3) | 37.35 | Neutral |
| ADX (14) | 19.31 | Neutral |
| Williams %R (14) | -43.37 | Neutral |
| ATR (14) | 0.45 | High Volatility |
| ROC (12) | 4.66 | Buy |
| Stoch RSI (14) | 49.51 | Neutral |
| UO (7,14,28) | 49.29 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Intimation Of Cut-Off Date/ Book Closure For The 33Rd Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=95535271-c923-41d0-bc63-d9b7c1fdc617.pdf) |
| 2026-09-05 | [Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d53c5b35-a2df-417b-ad52-28532a3b1303.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f2090bc-be10-43a4-bb7b-eb89d2f64d3f.pdf) |
| 2026-09-02 | [Notice Of 33Rd Annual General Meeting (AGM) For The FY 2025-2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a23fd705-97d2-4996-baba-80637a8bf445.pdf) |
| 2026-09-02 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a23b1ff5-80d0-4749-b37f-886e15790284.pdf) |
| 2026-09-02 | [Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For Letter Providing Web Link QR Code And Navigation Path For Accessing The Annual Report By The Shareholders Whose Email Ids Are Not Registered](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6826386e-aea3-4c0b-89d1-435ee082826d.pdf) |
| 2026-08-29 | [Board Meeting Outcome for Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1d9d278d-33e3-49f5-8a10-e66d87d3d745.pdf) |
| 2026-08-29 | [Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c19cfbdb-b303-4ea7-bdcc-7c2eddbd8f26.pdf) |
| 2026-08-29 | [Disclosure Under Regulation 30 Of SEBI (LODR) 2015 - Adoption Of New Line Of Business By The Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7f16e9a-41d9-4679-b19f-cefb0efafe6e.pdf) |
| 2026-08-29 | [Announcement under Regulation 30 (LODR)-Change in Directorate](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d7541604-e742-40d3-8eb3-614d8235fcaf.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Outcome Of The Board Meeting Held On August 12 2026 And Submission Of Unaudited Financial Results For The Quarter Ended June 30 2026 Under Regulation 30 & 33 Of The SEBI (LODR) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2912738f-8589-4dbd-a48d-7ac29baceede.pdf) |
| 2026-05-27 | [Audited Standalone Financial Results Of The Company For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34b3dede-f2e0-45c0-9958-f127418b0cbe.pdf) |
| 2026-01-31 | [Submission Of Unaudited Financial Results For The Quarter & Nine Months Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6232dfa0-12d9-4327-8960-af6c16f68751.pdf) |
| 2025-11-13 | [Results For The Quarter And Half Year Ended 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d07e5330-5822-4e71-9962-2f82c33d1539.pdf) |
| 2025-08-12 | [Submission Of Standalone Un-Audited Financial Results For The Quarter Ended 30Thjune 2025 As Required U/R 33 Of The SEBI (LODR) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=447d3ec7-4480-48e1-9ae0-17b55b229fe4.pdf) |
| 2025-05-29 | [Submission Of Audited Financial Results For The Quarter And Financial Year Ended 31St March 2025 As Required U/R 33 Of The SEBI (LODR) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd4f1736-437a-4861-99d1-534b58a594cf.pdf) |
| 2025-05-28 | [Financial Results For The Quarter And Financial Year Ended 31St March 2025 As Required U/R 33 Of The SEBI (LODR) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c82af6f-cdd5-4d74-8b6e-a850014d7a07.pdf) |
| 2025-02-07 | [Submission Of Standalone Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2024 As Required U/R 33 Of The SEBI (LODR) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9000969c-f7eb-4e88-b028-d93592fa3027.pdf) |
| 2024-11-13 | [Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3d4a147-f5bb-4370-b207-704478aeeb1d.pdf) |
| 2024-08-12 | [Submission Of Un-Audited Financial Results For The Quarter Ended 30Th June, 2024 As Required U/R 33 Of The SEBI (LODR) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d89a3239-3dc0-4f8f-8bbc-6fbd48cc3421.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Optival subsidiary: three-day Telangana drug-license suspension; order received 22-Feb-2026; potential revenue loss Rs 0.76 lakh. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 9h - Optival subsidiary: three-day Telangana drug-license suspension; order received 22-Feb-2026; potential revenue loss Rs 0.76 lakh.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/e223c4f0-fa57-4ba5-838e-c6b5064fa503.pdf) |
| 9h - Optival subsidiary got three-day drug-license suspension (Baragarh, Odisha) on 09.03.2026; potential revenue loss Rs 1.38 lacs. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 9h - Optival subsidiary got three-day drug-license suspension (Baragarh, Odisha) on 09.03.2026; potential revenue loss Rs 1.38 lacs.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/25fa3be6-296e-4d5d-b3be-7b030058cea6.pdf) |
| 9h - Board approved new MOA/AOA, shifting office to Delhi, and EGM on 25 May 2026. | [Announcement under Regulation 30 (LODR)-Change in Registered Office Address 9h - Board approved new MOA/AOA, shifting office to Delhi, and EGM on 25 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/5897df64-91c9-446b-8076-e5ec6d404436.pdf) |
| 9h - Board approved new MOA/AOA, Delhi office shift, and EGM on 25 May 2026. | [Board Meeting Outcome for Outcome Of Board Meeting 9h - Board approved new MOA/AOA, Delhi office shift, and EGM on 25 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/e53f897d-7ca8-4dbe-aad2-37f9a144c473.pdf) |
| 9h - Board approved new MOA/AOA and shift of registered office from Haryana to Delhi; EGM on 25 May 2026. | [Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association 9h - Board approved new MOA/AOA and shift of registered office from Haryana to Delhi; EGM on 25 May 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/85e02dc1-6b09-4f57-9037-1421a0c0e762.pdf) |
| 6 Feb - Resignation of Rachit Garg and appointment of Faizal Khader effective 21 Jan 2026; resignation letter resubmitted. | [Clarification For Announcement Under Regulation 30 SEBI (LODR), 2015- Resignation Of Mr. Rachit Garg, (DIN: 07574194), Non Executive Director Of The Company 6 Feb - Resignation of Rachit Garg and appointment of Faizal Khader effective 21 Jan 2026; resignation letter resubmitted.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/732f9ae6-9fa7-4bfa-b4e6-2356bb4bc892.pdf) |
| 6 Feb - Resignation of Mr Rachit Garg; appointment of Mr Faizal Khader effective 21.01.2026; resignation letter resubmitted. | [Announcement under Regulation 30 (LODR)-Resignation of Director 6 Feb - Resignation of Mr Rachit Garg; appointment of Mr Faizal Khader effective 21.01.2026; resignation letter resubmitted.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d1044f9d-0dd7-425f-896a-7779b94c288c.pdf) |
| 4 Feb - Q3 FY26 earnings call transcript: consolidated revenue ₹18,061 million; net +182 stores; network 5,112 stores. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 4 Feb - Q3 FY26 earnings call transcript: consolidated revenue ₹18,061 million; net +182 stores; network 5,112 stores.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c935bd94-16a3-41b0-94b4-0c760a24d32e.pdf) |
| 4 Feb - Optival subsidiary's Pune store drug-license suspended 15 days; order received 03.02.2026; potential Rs 6.27 lakh loss. | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 4 Feb - Optival subsidiary's Pune store drug-license suspended 15 days; order received 03.02.2026; potential Rs 6.27 lakh loss.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fc1c4fb2-e5d1-4a48-b0c1-992e085f272a.pdf) |
| 31 Jan - Optival Health subsidiary's Maharashtra store drug-license suspended 25 days; potential revenue loss Rs 7.53 lakhs (order received 30.01.2026). | [Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015 31 Jan - Optival Health subsidiary's Maharashtra store drug-license suspended 25 days; potential revenue loss Rs 7.53 lakhs (order received 30.01.2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a7f365a2-1307-4ca6-a103-58cd54433d8b.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/17d3948b-8f61-48be-a44f-25844f4de67f.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/MEDPLUS_16112024174113_EarningcalltranscriptQ2FY25.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1bd7ec45-f21c-4a5c-808c-cd2d85be2d58.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f11c0560-be9f-4f39-ad68-575342c7ac00.pdf) |
| Jun 2022 | [Concall - Jun 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3722c26f-08cc-4fb3-806b-440d437612f2.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/14164f35-ba32-40c3-a777-e1a006a01d3c.pdf) |
| Feb 2024 | [Concall - Feb 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e23357f8-57ec-4245-b0c3-f62c7065c574.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c89d5ed2-ac56-4582-afd2-7ab62364b5de.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c2b22a1b-19ed-44c7-bc15-a539bf3b8ebb.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f044fffc-ef5d-428a-ba4d-da6d67090822.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2022 from nse](https://archives.nseindia.com/annual_reports/AR_21283_MEDPLUS_2021_2022_03092022235403.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c50cab30-1147-4715-be23-951f30d4d169.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/32177362-6f26-4804-901a-f49bc8e163c9.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/20fec675-ac0a-4024-aa4f-65737e9595f8.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6203286f-ba69-404c-b555-09089ee229b0.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1546d6cd-042c-40b9-83c3-3cd737a683f7.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d87951de-a0e2-435d-9a1f-12b7fbc73667.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/536965/75575536965.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/543427/75886543427.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/536965/71060536965.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:58:43.384Z.